GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes. The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes. Read More
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The company’s continuous blood glucose monitor demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company said.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
